Patents Assigned to Afferent Pharmaceuticals, Inc.
  • DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH
    Publication number: 20220143015
    Abstract: Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Kathleen Sereda Glaub, Michael M. Kitt, Steven Smith
  • Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
    Patent number: 11260056
    Abstract: Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: March 1, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Anthony P. Ford, Kathleen Sereda Glaub, Michael M. Kitt, Steven Smith
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 11230532
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: January 25, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Crystalline salts and polymorphs of a P2X3 antagonist
    Patent number: 11230533
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: January 25, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE
    Publication number: 20210171505
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 10, 2021
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
    Patent number: 10988460
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 27, 2021
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 10822311
    Abstract: The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 3, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • CRYSTALLINE SALTS AND POLYMORPHS OF A P2X3 ANTAGONIST
    Publication number: 20200255386
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20200239421
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE
    Publication number: 20200239451
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 30, 2020
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Crystalline salts and polymorphs of a P2X3 antagonist
    Patent number: 10676444
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 9, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 10662162
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: May 26, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS
    Publication number: 20200108065
    Abstract: Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.
    Type: Application
    Filed: December 5, 2019
    Publication date: April 9, 2020
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Julian Paton
  • Methods and compositions for treating diseases and conditions
    Patent number: 10543211
    Abstract: Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: January 28, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Julian Paton
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20190389811
    Abstract: The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: March 9, 2017
    Publication date: December 26, 2019
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • CRYSTALLINE SALTS AND POLYMORPHS OF A P2X3 ANTAGONIST
    Publication number: 20190315698
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 17, 2019
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS
    Publication number: 20190175593
    Abstract: Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Julian Paton
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20190055202
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: March 20, 2017
    Publication date: February 21, 2019
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough
    Patent number: 10206922
    Abstract: Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: February 19, 2019
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Bruce G. McCarthy
  • Methods and compositions for treating diseases and conditions
    Patent number: 10195198
    Abstract: Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 5, 2019
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Julian Paton